

# QUARTERLY INVESTMENT REVIEW

# Small Cap Quality Strategy

## Performance returns (USD)

ANNUALIZED RETURNS (QUARTER-END)	Quarter-End	YTD	1-Year	3-Year	5-Year	10-Year	Since Inception
Small Cap Quality Strategy (net)	1.92	-3.26	-6.63	16.82	-	-	13.21
Small Cap Quality Strategy (gross)	2.12	-2.72	-5.92	17.69	-	-	14.05
S&P 600	9.11	4.24	3.64	12.81	-	-	8.72
Value Add	-7.19	-7.51	-10.26	+4.00	-	-	+4.49

#### MAJOR PERFORMANCE DRIVERS

The U.S. market rallied strongly this quarter, as fears of tariffs abated and excitement about AI and rate cuts contributed to an increasingly euphoric market. The S&P 500 rose 8.1% in the quarter, while our benchmark, the more cyclical S&P 600, rose 9.1%.

The Small Cap Quality portfolio rose over the period but underperformed the benchmark. August was a remarkably difficult month for us, as cyclical elements of the market performed strongly while defensive names lagged.

Throughout the quarter, our sector selection was favorable, with our overweights in Industrials and IT and an underweight in Financials contributing positively, partially offset by an overweight to Consumer Staples. Sector allocation was more than offset by stock selection headwinds. Indeed, within all sectors except Consumer Staples, our stock selection was negative. When we see stock selection underperformance (or outperformance) across a broad range of sectors, it suggests a factor move is driving much of our relative returns, and our measures of the performance of broader quality suggest the same: this was a very difficult period for quality investing.

Our weights in Aaon, Fabrinet, and Allegion were the largest positive contributors to our relative returns, while our investments in AptarGroup, Jack Henry, and Aramark were our largest detractors.

Aaon manufactures semi-custom high-end HVAC equipment, and several years ago bought BasX, a manufacturer of HVAC equipment for data centers and clean rooms. After some struggles with ramping up BasX production and switching to a new ERP, positive updates on their operational improvements, combined with growing recognition of their opportunity in data centers, led to share price improvement.

#### RISKS

Risks associated with investing in the Strategy may include: (1) Management and Operational Risk: the risk that GMO's investment techniques will fail to produce desired results, including annualized returns and annualized volatility; (2) Market Risk - Equities: the market price of equities may decline due to factors affecting the issuer, its industries, or the economy and equity markets generally. Declines in stock market prices generally are likely to reduce the net asset value of the Fund's shares; and (3) Smaller Company Risk: Smaller companies may have limited product lines, markets, or financial resources, lack the competitive strength of larger companies, have less experienced managers or depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. This is not a complete list of risks associated with investing in the Strategy. Please contact GMO for more information.

### Composite Inception Date: 31-Aug-22

Performance Returns: Performance for the year of inception is less than a full calendar year. Returns shown for periods greater than one year are on an annualized basis. To obtain performance information to the most recent month-end, visit www.gmo.com. Performance data quoted represents past performance and is not predictive of future performance. Net returns are presented after the deduction of a model advisory fee and incentive fee if applicable. These returns include transaction costs, commissions and withholding taxes on foreign income and capital gains and include the reinvestment of dividends and other income, as applicable. Fees paid by accounts within the composite may be higher or lower than the model fees used. Gross returns are presented gross of management fees and any incentive fees if applicable. These returns include transaction costs, commissions, withholding taxes on foreign income and capital gains and include the reinvestment of dividends and other income, as applicable. If management and incentive fees were deducted performance would be lower. For example, if, before fees, the strategy were to achieve a 10% annual rate of return above its hurdle rate each year for ten years, and an annual advisory fee of 1% and incentive fee of 20% of net returns above the hurdle rate were charged during that period, the resulting average annual net return (after the deduction of management and incentive fees) would be approximately 7.20%. GMO LLC claims compliance with the Global Investment Performance Standards (GIPS®). A Global Investment Performance Standards (GIPS®) Composite Report is available at www.gmo.com by clicking the GIPS® Composite Report link in the documents section of the strategy page. GIPS® is a registered trademark owned by CFA Institute. CFA Institute does not endorse or promote this organization, nor does it warrant the accuracy or quality of the content contained herein. Actual fees are disclosed in Part 2 of GMO's Form ADV and are also available in each strategy's Composite Report. T



# QUARTERLY INVESTMENT REVIEW

### MAJOR PERFORMANCE DRIVERS CONT.

Fabrinet is an outsourced manufacturer of optical networking equipment; Nvidia's networking division is its largest customer today. The stock performed poorly on earnings due to lackluster growth in its Nvidia-derived business but recovered strongly as the market priced in its strong and likely-accelerating growth into next year.

Allegion manufactures locks and related security products. The stock benefited from strong earnings results and a broader uplift in the shares of more cyclical businesses.

AptarGroup manufactures closures for pharmaceuticals and consumer goods. Their pharma segment, benefiting from regulatory barriers to entry, drives a disproportionate amount of the company's profitability. A weak quarter, with pharma growth impacted by destocking of cold and flu medicine and a slowdown in Narcan sales, weighed on the stock. It suffered from broader weak returns of defensive companies through the period.

Jack Henry provides software for banks, and focuses on banking "cores," the central systems of banks that maintain records of accounts, deposits, loans, etc. This quarter, the bank delivered fine earnings but was pressured by a broader sell-off in software, and the perception that rising bank M&A is increasingly becoming a headwind to the name. A large customer, though one worth <1% of revenue, was acquired, and its core will transition to competitor FIS. Jack Henry was also impacted by the weak returns of defensive names throughout the period.

Aramark provides outsourced food services and facilities management to schools, hospitals, stadiums, and other businesses. A somewhat soft 3Q result, combined with a full-year guide that implies significant acceleration in 4Q, led to a weak share price reaction. The stock also traded poorly throughout the period with other defensives.

This quarter was a difficult one for our portfolio. Our portfolio will have difficulty outperforming in markets where the most cyclical and speculative names do best. Over time, however, we believe that focusing on high quality businesses will lead to outsized returns with less downside risk. Through careful risk control at the portfolio level, we limit our exposure to bets on value or growth, or difficult-to-predict macroeconomic trends such as the trajectory of interest rates. Instead, we focus on identifying companies benefiting from strong competitive advantages, healthy balance sheets, and good management teams that are available at attractive valuations.

Portfolio weights, as a percent of equity, for the positions mentioned were: Aaon (4.2%), Fabrinet (4.4%), Allegion (4.4%), AptarGroup (3.7%), Jack Henry (2.9%), and Aramark (3.7%).



# QUARTERLY INVESTMENT REVIEW

### PRODUCT OVERVIEW

The GMO Small Cap Quality Strategy seeks to generate total return by investing primarily in equities of U.S. small cap companies that the Focused Equity team believes to be of high quality.

The team believes that companies with established track records of historical profitability and strong fundamentals – high quality companies – are able to outgrow the average company over time and are therefore worth a premium price. The Strategy's disciplined approach uses both quantitative and fundamental techniques to assess the relative quality and valuation of U.S. small cap companies and aims to exploit a long-term investment horizon while withstanding short-term volatility.

#### IMPORTANT INFORMATION

Comparator Index(es): The S&P SmallCap 600® seeks to measure the small-cap segment of the U.S. equity market. The index is designed to track companies that meet specific inclusion criteria to ensure that they are liquid and financially viable. S&P does not guarantee the accuracy, adequacy, completeness or availability of any data or information and is not responsible for any errors or omissions from the use of such data or information. Reproduction of the data or information in any form is prohibited except with the prior written permission of S&P or its third party licensors.

The above information is based on a representative account in the Strategy selected because it has the fewest restrictions and best represents the implementation of the Strategy.

For private bank intermediaries in Singapore and Hong Kong, these materials are intended for institutional and Accredited/Professional Investors Use Only.

### **ABOUT GMO**

Founded in 1977, GMO is a global asset manager committed to delivering superior performance and advice to our clients. We are privately owned, which allows us to singularly focus on our sole business – achieving outstanding long-term client investment outcomes. Offering multi-asset, equity, fixed income, and alternative strategies, we invest with a long-term, valuation-based philosophical approach.

AMSTERDAM BOSTON LONDON SAN FRANCISCO\* SINGAPORE SYDNEY TOKYO\*\*